华邦健康(002004) - 002004华邦健康投资者关系管理信息20260325

Group 1: Company Strategy and Business Focus - The company is committed to focusing on its core business, emphasizing the "big health" development strategy in pharmaceuticals and healthcare [2] - In pharmaceuticals, the company aims to enhance its integrated development model, covering raw materials, formulations, functional skincare products, and skin health management [2][3] - The healthcare segment includes basic medical care, rehabilitation, and longevity services, creating a comprehensive health ecosystem for customers [2][4] Group 2: Pharmaceutical Business Overview - The pharmaceutical business involves the research, production, and sales of drug formulations and raw materials, with a focus on skin, anti-infection, and anti-tumor products [3] - The company has three raw material production bases, ensuring a stable supply of core products and establishing long-term partnerships with international pharmaceutical companies [3] - The company holds a 13.2% stake in a gene therapy company, making it the third-largest shareholder [3] Group 3: Healthcare Services - The healthcare services include basic medical treatment, rehabilitation, and health management, providing integrated services to improve patient health and longevity [4][5] - The company operates various medical institutions that collaborate on resources, technology, and training to enhance service quality [7] Group 4: Tourism Business - The tourism segment includes operations in scenic area transportation, hotel management, and tourism performances, primarily in five major 5A scenic spots [9] - The company aims to enhance its core competitiveness and improve management levels across its business segments, including tourism [9] Group 5: Financial Performance Projections - For 2025, the company expects a net profit attributable to shareholders between 66 million and 73 million, representing a year-on-year growth of 320.74% to 344.16% [9] - The net profit after excluding non-recurring gains is projected to be between 60 million and 67 million, indicating a growth of 277.59% to 298.31% compared to the previous year [9]